DNA Contamination Study Using Holotype HLA v2

03/07/2019

EFI 2019 User Group Meeting presentation by Dr. Dominique Masson (EFS HLA Laboratory, Grenoble), including analysis using Omixon’s HLA Twin software and featuring test results. The presentation can be downloaded from here…

Loss of Heterozygosity – “Cancer Mimicry”

27/06/2019

Article written by Vera Siffnerova (FAS, Omixon) In most Slavic languages, LOH stands for Summer Olympic Games (e. g. Letní Olympijské Hry in Czech), in HLA world, LOH is known as an abbreviation of an important disease marker – Loss of Heterozygosity – during which different types of cancer...

“Omixon is a Company that Prides Itself in the Support of Customers” – Interview with Efi Melista, Head of Product

27/06/2019

The following interview is part of the Omixon interview series that we are conducting with Key Opinion Leaders, Experts and Business Managers at Omixon. Today Efi Melista, Head of Product answers various questions related to her professional background and product management at Omixon. What made you choose to be a...

Omixon Opens New Warehouse in Budapest, Hungary

27/06/2019

Omixon is growing! With more than 100,000 samples being shipped in 2019, we are growing our logistics operations to keep pace and provide more customized shipping services for unique requirements and customs processes. To further develop our capabilities in this area, we are delighted to announce a new Omixon...

Interfacing an NGS Bioinformatic Pipeline with Laboratory Information Management System

26/06/2019

Dr. Valia Bravo-Egana (Medical College of Georgia) had a presentation at our EFI 2019 User Group Meeting about NGS bioinformatic pipelines for the use of high resolution HLA typing results and reporting, including the handling of these high resolution results in clinical labs and LIMS implementations. You can...